The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
Dosage individualization for a critical care patient treated with amikacin for suspected ventilator-associated pneumonia, using the population pharmacokinetic (ppk) model of Burdet et al. 2015, using the data from therapeutic drug monitoring (TDM).
mod_amikacin_Burdet2015 <- function() {
ini({
THETA_Cl=4.3
THETA_Vc=15.9
THETA_Vp=21.4
THETA_Q=12.1
ETA_Cl + ETA_Vc + ETA_Vp + ETA_Q ~
c(0.1,
0.01 , 0.05 ,
0.01 , 0.02 , 0.2 ,
-0.06 , 0.004, 0.003, 0.08)
add_sd <- 0.2
prop_sd <- 0.1
})
model({
TVCl = THETA_Cl*(CLCREAT4H/82)^0.7
TVVc = THETA_Vc*(TBW/78)^0.9*(PoverF/169)^0.4
TVVp = THETA_Vp
TVQ = THETA_Q
Cl = TVCl*exp(ETA_Cl)
Vc = TVVc*exp(ETA_Vc)
Vp = TVVp*exp(ETA_Vp)
Q = TVQ *exp(ETA_Q)
ke = Cl/Vc
k12 = Q/Vc
k21 = Q/Vp
Cp = centr/Vc
d/dt(centr) = - ke*centr - k12*centr + k21*periph
d/dt(periph) = + k12*centr - k21*periph
Cp ~ add(add_sd) + prop(prop_sd) + combined1()
})
}
After the first administration, the dosage selection can be refined
using the results of TDM. See
vignette("patient_data_input")
for more details regarding
the patient record.
df_patientA <- data.frame(ID=1,TIME=c(0,1,6),
DV=c(NA,58,14),
EVID=c(1,0,0),
AMT=c(2000,0,0),
DUR=c(0.5,NA,NA),
CLCREAT4H=50,TBW=62,PoverF=169)
df_patientA
#> ID TIME DV EVID AMT DUR CLCREAT4H TBW PoverF
#> 1 1 0 NA 1 2000 0.5 50 62 169
#> 2 1 1 58 0 0 NA 50 62 169
#> 3 1 6 14 0 0 NA 50 62 169
The concentration measured 30 min after a 30 min infusion do not meet the target for a peak concentration; it is < 60 mg/L.
The maximum a posteriori (MAP) individual parameters are estimated.
The individual pharmacokinetic profile can be plotted using the
rxode2
model provided by the poso_estim_map()
function.
With the MAP estimates of the individual parameters, the prediction of the time needed before reaching the target Cmin can be updated.
poso_time_cmin(dat=df_patientA,
prior_model=mod_amikacin_Burdet2015,
tdm = TRUE,
target_cmin = 2.5)
#> $time
#> [1] 33.9
#>
#> $type_of_estimate
#> [1] "point estimate"
#>
#> $cmin_estimate
#> [1] 2.487865
#>
#> $indiv_param
#> THETA_Cl THETA_Vc THETA_Vp THETA_Q add_sd prop_sd ETA_Cl ETA_Vc
#> 3 4.3 15.9 21.4 12.1 0.2 0.1 0.4499479 0.2730561
#> ETA_Vp ETA_Q CLCREAT4H TBW PoverF
#> 3 0.7061648 -0.13884 50 62 169
The next dose (if needed) can be administered 33.9 hours following the first infusion.
The optimal dose to achieve a peak concentration of 80 mg/l can be determined using the MAP estimates.
map_dose <- poso_dose_conc(dat=df_patientA,
prior_model=mod_amikacin_Burdet2015,
tdm=TRUE,
time_c = 35, #target concentration at t = 35 h
time_dose = 34, #dosing at t = 34 h
duration = 0.5,
target_conc = 80)
map_dose
#> $dose
#> [1] 2447.917
#>
#> $type_of_estimate
#> [1] "point estimate"
#>
#> $conc_estimate
#> [1] 80
#>
#> $indiv_param
#> THETA_Cl THETA_Vc THETA_Vp THETA_Q add_sd prop_sd ETA_Cl ETA_Vc
#> 3 4.3 15.9 21.4 12.1 0.2 0.1 0.4499608 0.2730596
#> ETA_Vp ETA_Q CLCREAT4H TBW PoverF
#> 3 0.7061496 -0.1388505 50 62 169
The next dose should be 2450 mg.
The optimal inter-dose interval to reach a Cmin of 2.5 mg/L before each dosing can be determined using the MAP estimates.
map_interval <- poso_inter_cmin(dat=df_patientA,
prior_model=mod_amikacin_Burdet2015,
dose = map_dose$dose,
duration = 0.5,
target_cmin = 2.5)
map_interval
#> $interval
#> [1] 38.57781
#>
#> $type_of_estimate
#> [1] "point estimate"
#>
#> $conc_estimate
#> [1] 2.500173
#>
#> $indiv_param
#> THETA_Cl THETA_Vc THETA_Vp THETA_Q add_sd prop_sd ETA_Cl ETA_Vc
#> 1 4.3 15.9 21.4 12.1 0.2 0.1 0.449952 0.2730587
#> ETA_Vp ETA_Q CLCREAT4H TBW PoverF
#> 1 0.7061588 -0.1388432 50 62 169
The interval between doses should not be less than 38.6 hours to allow adequate elimination of amikacin between each infusion.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.